Travere Therapeutics (TVTX) Leases (2019 - 2025)
Historic Leases for Travere Therapeutics (TVTX) over the last 7 years, with Q3 2025 value amounting to $11.5 million.
- Travere Therapeutics' Leases fell 2680.37% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year decrease of 2680.37%. This contributed to the annual value of $14.3 million for FY2024, which is 2085.16% down from last year.
- According to the latest figures from Q3 2025, Travere Therapeutics' Leases is $11.5 million, which was down 2680.37% from $12.3 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Leases ranged from a high of $25.0 million in Q1 2021 and a low of $11.5 million during Q3 2025
- Over the past 5 years, Travere Therapeutics' median Leases value was $19.2 million (recorded in 2023), while the average stood at $18.7 million.
- Its Leases has fluctuated over the past 5 years, first tumbled by 3295.95% in 2021, then plummeted by 946.71% in 2022.
- Quarter analysis of 5 years shows Travere Therapeutics' Leases stood at $23.2 million in 2021, then dropped by 9.47% to $21.0 million in 2022, then decreased by 14.0% to $18.1 million in 2023, then dropped by 20.85% to $14.3 million in 2024, then fell by 19.8% to $11.5 million in 2025.
- Its Leases was $11.5 million in Q3 2025, compared to $12.3 million in Q2 2025 and $13.2 million in Q1 2025.